Date: 2014-05-05
Type of information: Services contract
Compound: target discovery project
Company: Cenix Bioscience (Germany) Bayer (Germany)
Therapeutic area: undisclosed
Type agreement: services
Action mechanism:
Disease: undisclosed
Details: * On May 5, 2014, Cenix BioScience, a preclinical contract research provider and technology developer specialized in RNAi- based genomics and high content screening-driven pharmacology, announced that is has signed a research service agreement with Bayer Pharma AG. Under the agreement, Cenix will undertake a target discovery project for an undisclosed disease indication by applying its longstanding industry-leading expertise in high throughput RNAi for genome-scale screening in advanced cell models.
Financial terms: Financial terms were not disclosed.
Latest news:
